Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention Deficit Clear all
Completed No phase listed Observational

Pediatric Bipolar Disorder Study at UCLA

NCT00961935
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

NCT03605849
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

NCT00181948
View directory record Official record
Conditions
ADHD
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine, Lisdexamfetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT02734693
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline 4mg, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

NCT00142961
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions
Atomoxetine, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 16, 2026, 10:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01133028
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Behavioral contingency management, Tolerance training
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 8 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community

NCT01056016
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADHD Collaborative
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD

NCT02674633
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
AKL-T01, AKL-T09
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Dothan, Alabama • Scottsdale, Arizona • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2)

NCT01490307
View directory record Official record
Conditions
Substance Use, Conduct Disorder, Depression, Anxiety
Interventions
Family Check-Up
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
Not listed
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 11, 2011 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Not applicable Interventional

ADHD/Me Bibliotherapy Study

NCT03620344
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADH-Me Book and ADHD Informational Brochure, ADHD Informational Brochure Only
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 10 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers

NCT01919073
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders
Interventions
Immediate Treatment Group, Delayed Treatment Group
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 5 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

NCT03533556
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-theanine, Caffeine, L-theanine-Caffeine Combination, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)

NCT02900144
View directory record Official record
Conditions
Tourette Syndrome, ADHD
Interventions
Modified Comprehensive Behavioral Intervention for Tics, Comprehensive Behavioral Intervention for Tics
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Effectiveness Evaluation of a Comprehensive School Readiness Summer Program for Young Children At-Risk

NCT07445867
View directory record Official record
Conditions
Externalizing Behavior
Interventions
Summer Academy
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
4 Years to 6 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02547428
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN SR, Matching placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antipsychotics in Children

NCT00205699
View directory record Official record
Conditions
Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions
risperidone, olanzapine, aripiprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

NCT05608434
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Floreo Virtual Reality application
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 16 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01081145
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

NCT06973577
View directory record Official record
Conditions
ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions
Centanafadine, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 16, 2026, 10:45 AM EDT
Not listed Phase 1 Interventional

Treatment of Conduct Problems and Depression

NCT01267773
View directory record Official record
Conditions
Depression, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Integrated Treatment
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
8 Years to 14 Years
Enrollment
30 participants
Timeline
2010 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

NCT07389473
View directory record Official record
Conditions
ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic Medications
Drug
Lead sponsor
Gaize
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 16, 2026, 10:45 AM EDT